Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Gastrointestinal 1

Conditions

KRAS p.G12C Mutant Advanced Solid Tumors 1

Interventions

Nivolumab 3Ipilimumab 3pembrolizumab 2entrectinib 2cobimetinib 2Pemetrexed 2Cisplatin 2tovorafenib 1sotorasib 1relatlimab 1pralsetinib 1larotrectinib 1ipatasertib 1inavolisib 1daratumumab 1atezolizumab 1alectinib 1PM 01183 1Midazolam 1Carboplatin 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × sotorasib × Other solid neoplasm × Clear all
NCT03600883 2026-03-16

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Amgen

Phase 1/2 Active not recruiting
713 enrolled 1 FDA
Other solid neoplasm

KRAS p.G12C Mutant Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡